Product Name:(R)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine

IUPAC Name:O-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}hydroxylamine

CAS:114778-50-6
Molecular Formula:C6H13NO3
Purity:95%
Catalog Number:CM122019
Molecular Weight:147.17

Packing Unit Available Stock Price($) Quantity
CM122019-1g in stock ǟţħ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:114778-50-6
Molecular Formula:C6H13NO3
Melting Point:-
Smiles Code:NOC[C@@H]1OC(C)(C)OC1
Density:
Catalog Number:CM122019
Molecular Weight:147.17
Boiling Point:
MDL No:MFCD09263188
Storage:Store at 2-8°C.

Category Infos

Dioxolanes
Dioxolane is a heterocyclic acetal with the formula (CH2)2O2CH2. It is related to tetrahydrofuran by exchanging an oxygen for the CH2 group. The isomer 1,2-dioxolane (in which the two oxygen centers are adjacent) is a peroxide. 1,3-Dioxolane is used as solvent and comonomer in polyacetal. The dioxolane-type and their hydrogenolysis can provide very valuable partially protected building blocks either for oligosaccharide syntheses or sugar transformations.

Column Infos

Alicyclic Heterocycles
When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.
Mirdametinib
SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.